SCHEMBL2089002

SCHEMBL2089002

[CH2]OC(=O)N(c1ccccc1)c1cccc(Cl)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NPSR1 Q6W5P4 3/20 0.39
TSHR P16473 1/20 0.39
PTGIR P43119 2/20 0.38
KMT2A Q03164 5/20 0.38
ALDH1A1 P00352 3/20 0.38
POLB P06746 2/20 0.38
NPC1 O15118 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
MCOLN3 Q8TDD5 1/20 0.37
CACNA2D1 P54289 1/20 0.36
CACNA1B Q00975 1/20 0.36
CACNB1 Q02641 1/20 0.36
CACNA1C Q13936 1/20 0.36
MEN1 O00255 2/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2089007 0.85 PTGIR (0.41) ATMTDP1L3MBTL1NPSR1TSHR
SCHEMBL6003085 0.84 PTGIR (0.39) ATMTDP1L3MBTL1NPSR1TSHR
SCHEMBL2091321 0.82 NPSR1 (0.45) ATMTDP1L3MBTL1NPSR1TSHR
SCHEMBL2091316 0.81 NPSR1 (0.44) ATMTDP1L3MBTL1NPSR1TSHR
SCHEMBL27296911 0.78 NPSR1 (0.46) ATMTDP1L3MBTL1NPSR1TSHR
SCHEMBL6002286 0.78 L3MBTL1 (0.61) ATMTDP1L3MBTL1NPSR1TSHR
SCHEMBL2092800 0.76 TDP1 (0.43) ATMTDP1L3MBTL1NPSR1TSHR
SCHEMBL2095429 0.75 RAB9A (0.38) ATMTDP1L3MBTL1NPSR1TSHR
SCHEMBL2098121 0.74 ESR1 (0.43) ATMTDP1L3MBTL1NPSR1TSHR
SCHEMBL1118734 0.70 PTGIR (0.48) ATMTDP1L3MBTL1NPSR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 ATM 4071/4885TDP1 4548/4885L3MBTL1 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.